VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | An insight into the biology of CHIP and CCUS and their role in hematological malignancies

Amir T. Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, shares some insights into the biology of clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). Dr Fathi highlights the role of these precursor conditions in the development of myeloid malignancies, and further comments on the importance of closely monitoring patients with CHIP and CCUS in case of disease progression. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Clinical trial support – Abbvie, Servier, BMS
Consulting – Abbvie, Servier, BMS, Genentech, PureTech, Ipsen, Forma, Kite, Celgene, Amgen, Novartis, Takeda, Astellas, Immunogen, Mablytics, EnClear, Orum

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter